Format

Send to

Choose Destination
Am J Clin Oncol. 1992 Jun;15(3):256-9.

Phase II trial of recombinant tumor necrosis factor in disseminated malignant melanoma.

Author information

1
Division of Medical Oncology, Mayo Clinic, Rochester, Minnesota 55905.

Abstract

Twenty-one patients with disseminated malignant melanoma received recombinant tumor necrosis factor (TNF), 150 micrograms/m2 intravenously on days 1-5 every 2 weeks for four cycles and then every 3 weeks. Recombinant TNF produced no meaningful palliation. One patient (5%) attained an objective response of nodal, but not visceral, disease, which lasted 3 weeks. The median time to progression was 4 weeks. The median survival was 7.7 months. Ninety percent of patients developed mild to severe cytokine "flu." Ten percent developed significant hepatic toxicity (AST greater than 3 times normal). As a single agent, recombinant TNF is not likely to palliate disseminated malignant melanoma. However, combinations of recombinant TNF and cytotoxic or immune modulatory agents, particularly gamma interferon, may merit further investigation.

PMID:
1590281
[Indexed for MEDLINE]

Supplemental Content

Loading ...
Support Center